Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Geographic Atrophy, Age Related Macular Degeneration

In brief

The purpose of this study is to assess the Safety and Efficacy of IONIS-FB-Lrx for up to 120 patients with Geographic Atrophy secondary to Age Related Macular Degeneration

Key facts

Study ID
NCT03446144
Run by
Ionis Pharmaceuticals, Inc.
People needed
0
Starts
2018-03-16
Expected to finish
2018-10-10
Last updated by the study team
2019-08-13

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.